Riluzole NEW
| Price | $45 | $58 | $117 |
| Package | 50mg | 100mg | 500mg |
| Supply Ability: | 10g |
| Update Time: | 2026-04-20 |
Product Details
| Product Name: Riluzole | CAS No.: 1744-22-5 |
| Purity: 99.71% | Supply Ability: 10g |
| Release date: 2026/04/20 |
Product Introduction
Bioactivity
| Name | Riluzole |
| Description | Riluzole (RP-54274) is a glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS. |
| In vitro | Riluzole readily crosses the blood-brain barrier. Treatment of rodents with transient cerebral ischemia with 8 mg/kg i.p. Riluzole completely inhibited the massive release of glutamic acid induced by local ischemia. |
| In vivo | Riluzole readily crosses the blood-brain barrier. Treatment of rodents with transient cerebral ischemia with 8 mg/kg i.p. Riluzole completely inhibited the massive release of glutamic acid induced by local ischemia. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 240 mg/mL (1024.77 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (21.35 mM), Sonication is recommended. H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : 43 mg/mL (183.6 mM), Sonication is recommended. |
| Keywords | γ-Aminobutyric acid Receptor | SodiumChannel | Sodium Channel | RP54274 | RP 54274 | Riluzole | PK-26124 | PK26124 | NMDA receptor | Na+ channels | Na channels | Inhibitor | inhibit | Gamma-aminobutyric acid Receptor | GABAReceptor | GABA Receptor | GABA |
| Inhibitors Related | Phenytoin sodium | Procaine | p-Hydroxybenzaldehyde | Urethane | Penicillin G sodium salt | Valproic Acid | L-Aspartic aicd sodium | Methyl eugenol | (-)-α-Pinene | Memantine hydrochloride | Dihydromyricetin | Methionine |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Anti-Neurodegenerative Disease Compound Library | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP6Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2026-06-05 | ||
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-06-05 | ||
|
VIP3Y
|
Hangzhou Hyper Chemicals Limited
|
2026-05-29 | ||
| $1.90 |
VIP5Y
|
Hebei Chuanghai Biotechnology Co,.LTD
|
2026-05-28 | |
| $45.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-04-22 | |
| $1.10 |
VIP6Y
|
Dideu Industries Group Limited
|
2025-11-18 | |
|
VIP4Y
|
Dingwang Technology (Wuhan) Co., Ltd.
|
2025-08-22 | ||
| $45.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-04-30 | |
|
VIP3Y
|
Shaanxi TNJONE Pharmaceutical Co., Ltd
|
2025-04-02 | ||
| $66.00 |
Xiamen Wonderful Bio Technology Co., Ltd.
|
2024-01-18 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY